193 related articles for article (PubMed ID: 30697883)
1. The efficacy of omalizumab in Cutaneous Mastocytosis: A case series.
Hinojosa T; Lewis DJ; Vangipuram R; Safeer L; Mui UN; Haley C; Konoplev S; Tyring SK
Dermatol Ther; 2019 May; 32(3):e12848. PubMed ID: 30697883
[TBL] [Abstract][Full Text] [Related]
2. Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair
Hughes JDM; Olynyc T; Chapdelaine H; Segal L; Miedzybrodzki B; Ben-Shoshan M
Clin Exp Dermatol; 2018 Jul; 43(5):573-576. PubMed ID: 29451318
[TBL] [Abstract][Full Text] [Related]
3. Maculopapular Cutaneous Mastocytosis Successfully Treated with Omalizumab.
Tampouratzi L; Kanni T; Katsantonis J; Douvali T
Acta Dermatovenerol Croat; 2021 Apr; 291(1):60-61. PubMed ID: 34477069
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
[TBL] [Abstract][Full Text] [Related]
5. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
6. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Nayak A; Casale T; Miller SD; Condemi J; McAlary M; Fowler-Taylor A; Della Cioppa G; Gupta N
Allergy Asthma Proc; 2003; 24(5):323-9. PubMed ID: 14619332
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature.
Tonacci A; Billeci L; Pioggia G; Navarra M; Gangemi S
Pharmacotherapy; 2017 Apr; 37(4):464-480. PubMed ID: 28226418
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
10. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
[TBL] [Abstract][Full Text] [Related]
11. Approaches to target IgE antibodies in allergic diseases.
Balbino B; Conde E; Marichal T; Starkl P; Reber LL
Pharmacol Ther; 2018 Nov; 191():50-64. PubMed ID: 29909239
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature.
Li JX; Fan LC; Li MH; Cao WJ; Xu JF
Respir Med; 2017 Jan; 122():33-42. PubMed ID: 27993289
[TBL] [Abstract][Full Text] [Related]
13. Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study.
Cusack RP; Sahadevan A; Lane SJ
QJM; 2016 Sep; 109(9):601-4. PubMed ID: 26966102
[TBL] [Abstract][Full Text] [Related]
14. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM).
McComish JS; Slade CA; Buizen L; Paul SK; Chatelier JW; Unglik G; Nicholls KA; Spriggs K; Chan SS; Godsell J; Auyeung P; Tan ZH; DeLuca J; Patel M; Kuek LE; Tran Y; Kern JS; Scardamaglia L; Varigos GA; Juneja S; Grabek JA; Christie M; Mackay GA; Douglass JA
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2248-2250.e3. PubMed ID: 37088371
[No Abstract] [Full Text] [Related]
16. Suplatast tosilate for treating cutaneous mastocytosis.
Yasudo H; Ando T; Hiwatari M; Oka A
Pediatr Dermatol; 2015; 32(3):e118-9. PubMed ID: 25779849
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.
Lemal R; Fouquet G; Terriou L; Vaes M; Livideanu CB; Frenzel L; Barete S; Canioni D; Lhermitte L; Rossignol J; Arock M; Dubreuil P; Lortholary O; Hermine O
J Allergy Clin Immunol Pract; 2019; 7(7):2387-2395.e3. PubMed ID: 30954641
[TBL] [Abstract][Full Text] [Related]
18. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.
Barrios DM; Phillips GS; Geisler AN; Trelles SR; Markova A; Noor SJ; Quigley EA; Haliasos HC; Moy AP; Schram AM; Bromberg J; Funt SA; Voss MH; Drilon A; Hellmann MD; Comen EA; Narala S; Patel AB; Wetzel M; Jung JY; Leung DYM; Lacouture ME
Ann Oncol; 2021 Jun; 32(6):736-745. PubMed ID: 33667669
[TBL] [Abstract][Full Text] [Related]
19. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
Corren J; Shapiro G; Reimann J; Deniz Y; Wong D; Adelman D; Togias A
J Allergy Clin Immunol; 2008 Feb; 121(2):506-11. PubMed ID: 18269927
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.
Steiss JO; Schmidt A; Nährlich L; Zimmer KP; Rudloff S
Allergy Asthma Proc; 2012; 33(1):77-81. PubMed ID: 22370532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
